GCIA
DNA icon

Gabelli & Co Investment Advisers’s Ginkgo Bioworks DNA Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-375
Closed -$125K – 515
2021
Q4 		$125K Buy
+375
New +$178K 0.02% 374

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Gabelli & Co Investment Advisers's DNA Position: Q1 2022 in Review

Gabelli & Co Investment Advisers sold out of Ginkgo Bioworks (DNA) in Q1 2022, closing a stake of 375 shares — an estimated $125K sold.

Gabelli & Co Investment Advisers first reported a position in DNA in Q4 2021 and held it in 1 quarter. The position peaked at $125K in Q4 2021. 190 funds tracked by Wall St. Rank hold DNA as of Q1 2022.

  • Gabelli & Co Investment Advisers reported no remaining Ginkgo Bioworks position as of Q1 2022 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 375 Ginkgo Bioworks shares in Q1 2022, an estimated $125K.
  • Gabelli & Co Investment Advisers first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Ginkgo Bioworks position peaked at $125K in Q4 2021.
  • 190 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2022, filed 13 May 2022.